- Home
- AKA vs KZIA Comparison
AKA vs KZIA Comparison
Compare AKA & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AKA | KZIA |
|---|---|---|
| Founded | 2018 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.4M | 100.8M |
| IPO Year | 2021 | 2002 |
Fundamental Metrics
Financial Performance| Metric | AKA | KZIA |
|---|---|---|
| Price | $10.59 | $11.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $24.33 | $19.50 |
| AVG Volume (30 Days) | 3.3K | ★ 256.3K |
| Earning Date | 05-08-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $600,208,000.00 | N/A |
| Revenue This Year | $6.14 | N/A |
| Revenue Next Year | $4.89 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.44 | N/A |
| 52 Week Low | $7.00 | $3.05 |
| 52 Week High | $16.38 | $17.40 |
Technical Indicators
Market Signals| Indicator | AKA | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 51.97 | 67.61 |
| Support Level | $10.50 | $5.85 |
| Resistance Level | $11.82 | $14.42 |
| Average True Range (ATR) | 0.57 | 1.24 |
| MACD | 0.06 | 0.20 |
| Stochastic Oscillator | 53.01 | 78.22 |
Price Performance
Historical ComparisonAbout AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is a portfolio of fashion brands, including Princess Polly, Culture Kings, Petal & Pup, and mnml. Through these brands, the company reaches next-generation consumers who seek fashion inspiration on social media and mainly shop online. The portfolio consists of two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company generates the majority of its revenue from the United States.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.